DVL - DorsaVi Ltd

DorsaVi Ltd (DVL) is an Australian-based biotechnology company specialising in the development and commercialisation of wireless and wearable sensor movement monitoring products.

http://www.dorsavi.com

Errrm,
hi, let me introduce myself...

5 year chart.
Recent spike volume screaming for a upward correction...

I remember this one. In fact I put some money in, in the early days, rode the roller coaster for a while and then scrambled to get out. Whilst an interesting bit of tech, there was an inability of a small underfunded biz to get traction. At the same time, the big league with products like Fitbit and etc were gaining popularity. And Catapult at the pointy end boxed them in.

Sold, lost a few hundred but learnt from it. Good ideas don't make great businesses.

frugal.rock said:

Recent spike volume screaming for a upward correction...

Click to expand...

Dona Ferentes said:

I remember this one.

Click to expand...

I forgot. Bang.

I'm probably walking into a trap here but here goes ...... I'm taking DVL in the October Tipping Comp.
There looks to be a bit of interest in this stock over the last week or so with a lot more volume and higher prices. It is also out performing the XAO over this period of time.
Very high volume and a price spike to .27 on the 2nd July then plunged back to basically where it started from that day. The next day it reached a high of .06 which would be a nice target to aim for as a starter (76%)

8th Oct: Nice jump in price and volume but since then price keeps dropping each day with no interest .... even gone below the low of the bullish bar (8th)

Now I know why ... Trading Halt this morning with a smell of a Capital Raising. No chance of reaching my .06c target now.

frugal.rock said:

I forgot. Bang.

Click to expand...

@barney
I tell a lie, this is bio tech, I just didn't know anything about it, still don't ...
Shame about the timing @debtfree ?!

Wow ...... This rise was based on a 6 month evaluation agreement with "Medtronic" .... That is a good announcement but not immediately cash producing.

The current market has a real appetite for future potential, albeit a fleeting appetite at times

frugal.rock said:

Shame about the timing @debtfree ?!

Click to expand...

barney said:

Wow ...... This rise was based on a 6 month evaluation agreement with "Medtronic" .... That is a good announcement but not immediately cash producing.

Click to expand...

Yes, you are both quite right. The last few months have been a little bit of a tease and even if I did pick it again for Dec, by the end of the month big profits were gone.

One more try in the Jan 2021 Monthly Comp but I know it's probably going to disappoint. I'm trying to catch a 50-100% move in these Monthly Comps.

ST-EMAs have come back near the LT-EMAs. Price jumped above 10day MA 3 days ago and has since came back to the 38% mark of the move up from the low 4 days ago. Volume has dropped in the last 2 days.
That's as good as it gets, I aiming for the high of the bullish bar on the 10th Dec at 0.08 cents which would give me a 95% return. A really big ask and only time will tell.

Stampy Comp pick

Looking for continuation of this move after a small rest over the last 2 weeks followed by a new high .

Happy for all thoughts. Time will tell.

But .. she has already gone a long way so it could turn quickly as she has done in the past.

Anything can happen .



Regards
Stampy

this one has woken up



Key highlights
• dorsaVi secured an Exclusive Worldwide Licence to Advanced RRAM Technology
from NTU Singapore which provides a transformational IP portfolio to power next-generation smart sensors across healthcare, AI, and IoT.
• An internal evaluation of RRAM-enabled biomedical sensors with RRAM integration into dorsaVi sensors delivers significantly material gains, including up to 50x faster write speeds, >5,000x faster read access, and >10 million endurance cycles under biosignal workloads.
• dorsaVi signed a three year deal with leading mining health group - SANO Health.
• Extended business relationship for further 2 years with major Australian insurance company, following the success of the existing relationship.
• dorsaVi investing in final stages of security clearance for large clinical franchise groups in the US.
• US Surgeon Foot and ankle project for elite athletes was completed with exceptional results with next phase being planned for Q1 & Q2 FY26.
• A $2.44m Capital Raise was undertaken during Q4 with funds secured for RRAM development and to expand dorsaVi’s buisness in the US market.
• During the quarter, dorsaVi received cash receipts of $308k and had net operating cash outflow of $445k.
• dorsaVi holds cash balance of $2.293m at 30 June 2025.

.... 18 Aug
Key Highlights:
● Firm commitments received to raise $5 million (before costs) via a Placement to a restricted group of high-net-worth investors at $0.04 per Share.
● Strong demand received from both new and existing sophisticated and professional investors following recent securing of the exclusive worldwide RRAM licence.
● Proceeds will accelerate development and integration of dorsaVi’s RRAM-enabled sensor architecture, video-based AI platforms, and additional complementary innovations.